Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.31 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21915593 | 0.86 | HSD17B1 (0.31) | TP53HSD17B1HSD17B2 | |
| SCHEMBL21915538 | 0.86 | ALOX5 (0.39) | ALOX5PRKDCGGPS1TP53PTGES2 | |
| SCHEMBL21915588 | 0.81 | ALOX5 (0.33) | ALOX5PRKDC | |
| SCHEMBL15470296 | 0.80 | ALOX5 (0.44) | ALOX5PRKDCGGPS1TP53PTGES2 | |
| SCHEMBL21915589 | 0.80 | ALOX5 (0.39) | ALOX5PRKDCHSD17B1HSD17B2KDM4E | |
| SCHEMBL21915402 | 0.79 | HSD17B1 (0.35) | TP53HSD17B1HSD17B2KDM4E | |
| SCHEMBL21915499 | 0.79 | HSD17B1 (0.33) | HSD17B1HSD17B2 | |
| SCHEMBL21915371 | 0.79 | ALOX5 (0.41) | ALOX5PRKDCGGPS1PTGES2HSD17B1 | |
| SCHEMBL17278624 | 0.79 | ALOX5 (0.41) | ALOX5PRKDCGGPS1PTGES2KDM4E | |
| SCHEMBL21915426 | 0.78 | HSD17B1 (0.43) | HSD17B1HSD17B2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020062375-A1 | 1,2,4-THIADIAZOLE COMPOUNDS AND PREPARATION METHOD THEREFOR AND USE THEREOF | 武汉尚赛光电科技有限公司 | 2020-04-02 | — | — | WO | disclosed |